Opinion and Evidence in Neurology and Psychiatry
- PDF / 86,250 Bytes
- 7 Pages / 504.57 x 720 pts Page_size
- 107 Downloads / 213 Views
CNS Drugs 2003; 17 (4): 285-291 1172-7047/03/0004-0285/$30.00/0 © Adis Data Information BV 2003. All rights reserved.
Opinion and Evidence in Neurology and Psychiatry Contents Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 1. Early Sumatriptan Use Improves Outcomes, Cuts Costs in Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . 285 2. Paroxetine, Venlafaxine Improve Quality of Life in Obsessive-Compulsive Disorders . . . . . . . . . . . . 286 3. Rasagiline Monotherapy Beneficial in Early Parkinson’s Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 286 4. Paroxetine Effective Long-Term Therapy for Social Anxiety Disorder . . . . . . . . . . . . . . . . . . . . . . . . . . 287 5. Venlafaxine More Effective than SSRIs for Depression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287 6. Patient Education Reduces Benzodiazepine Use, Costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 287 7. Long-Term Clozapine Use Reduces Costs in Schizophrenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288 8. Dopamine Antagonists Increase Breast Cancer Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288 9. Xenon: The Future of Inhalational Anaesthesia? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 288 10. Therapeutic Options for Primary Brain Tumours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 289 11. Alteplase in Acute Ischaemic Stroke: More Evidence Needed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 290
Abstract
The management of neurological and psychiatric disorders is a vast and evolving area for researchers, primary care physicians and specialists. To help you keep up to date with the latest advances worldwide on all aspects of drug therapy for neurological and psychiatric disorders, this new section of the journal brings you information selected from the drug therapy reporting service Inpharma Weekly1. The following reports are selected from the latest issues, summarising the most important research and development news, clinical studies, treatment guidelines, pharmacological, pharmacoeconomic and adverse drug reactions/ interactions news, and expert opinion pieces published across a broad range of literature sources.
1. Early Sumatriptan Use Improves Outcomes, Cuts Costs in Migraine Early migraine treatment with sumatriptan improves patient outcomes and reduces total costs, compared with delayed treatment, report US-based researchers. They developed a decision-analysis model, based on data from two published clinical trials and an analysis of patient diaries, to assess costs and
outcomes associated with sumatriptan [‘ImitrexEG’] 50 or 100mg for early migraine with mild pain, versus delayed treatment for moderate-to-severe pain. The mode
Data Loading...
